Medication info
Candomore Tablet 32 mg (Candesartan Cilexetil)

Candomore Tablet 32 mg (Candesartan Cilexetil)

Prescription medicationTabletOral
Ingredient · strength
Candesartan Cilexetil›32mg / 1 tablet
Manufacturer / importer
Jongkundang Co., Ltd.
Appearance
Light pink, double convex, round tablet
Packaging
28 tablets (14 tablets/PTP X 2)
Approval status
Active

MFDS item code 201007750 · Notified 2010.12.30 · Insurance code 643305900

Summary

Main use
Treatment of essential hypertension and heart failure with reduced left ventricular systolic function
Who takes it
Adults · Children
Adult dose
This medicine should be taken at the same time each day, regardless of meals. 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased up to a maximum of 32 mg once daily. If blood pressure is not controlled at this dose, other treatments should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: In patients at high risk of hypotension, such as those with reduced effective circulating blood volume, administer an initial dose of 4 mg with careful monitoring. 4) Patients with renal impairment: The initial dose in patients with renal impairment, including those undergoing hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience with use in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. 5) Patients with hepatic impairment: The initial dose in patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience with use in patients with severe hepatic impairment. 2. Heart failure 1) Adults: The recommended initial dose is 4 mg once daily. Double the dose at intervals of at least 2 weeks, taking the patient's tolerability into consideration, up to a maximum of 32 mg once daily. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary.
Child dose
1. Essential hypertension 6) Children: The safety and efficacy in adolescents and children aged 18 years or younger have not been established. 2. Heart failure 3) Children: The safety and efficacy in adolescents and children aged 18 years or younger have not been established.

Ingredients

Manufacturer
Jongkundang Co., Ltd.

Efficacy & effects

Treatment of essential hypertension and heart failure with reduced left ventricular systolic function

  • Essential hypertension
  • heart failure
  • impaired left ventricular systolic function
  • decreased left ventricular ejection fraction
View approved original text

This medication is used to effectively lower the blood pressure in patients with essential hypertension. It is also used in patients with heart failure who have impaired left ventricular systolic function and require treatment alongside ACE inhibitors or who cannot tolerate ACE inhibitors well. This helps reduce the burden on the heart and improve symptoms.

How to take

Adult dose

This medicine should be taken at the same time each day, regardless of meals. 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased up to a maximum of 32 mg once daily. If blood pressure is not controlled at this dose, other treatments should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: In patients at high risk of hypotension, such as those with reduced effective circulating blood volume, administer an initial dose of 4 mg with careful monitoring. 4) Patients with renal impairment: The initial dose in patients with renal impairment, including those undergoing hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience with use in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. 5) Patients with hepatic impairment: The initial dose in patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience with use in patients with severe hepatic impairment. 2. Heart failure 1) Adults: The recommended initial dose is 4 mg once daily. Double the dose at intervals of at least 2 weeks, taking the patient's tolerability into consideration, up to a maximum of 32 mg once daily. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary.

Child dose

1. Essential hypertension 6) Children: The safety and efficacy in adolescents and children aged 18 years or younger have not been established. 2. Heart failure 3) Children: The safety and efficacy in adolescents and children aged 18 years or younger have not been established.

Precautions

This drug can cause serious harm, particularly to the fetus and newborn, during pregnancy; therefore, it should be discontinued immediately upon confirmation of pregnancy. Patients with allergies to this drug, women who are pregnant or breastfeeding, patients with severe liver disease or cholestasis, patients with hereditary angioedema, and patients with certain genetic lactose intolerance should avoid taking this medication. Elderly patients, those with hyperkalemia, liver dysfunction, heart valve disease, ischemic heart disease, and kidney disease should use this drug with caution and closely monitor their condition before and during administration. Common side effects of this drug include dizziness, back pain, respiratory infections, while serious side effects may rarely include severe liver dysfunction, blood disorders, skin rash, muscle pain, and worsening kidney function. In patients with heart failure, blood pressure reduction, hyperkalemia, and kidney function impairment may occur, necessitating regular blood tests and monitoring. The effect of this drug may be enhanced when used with other antihypertensive agents, so caution should be exercised regarding interactions with other medications being taken. Particularly, when used in combination with potassium-sparing diuretics or potassium supplements, serum potassium levels may rise dangerously, and caution is necessary. Women who are pregnant or planning to become pregnant should avoid using this drug, and it is advisable to avoid administering it while breastfeeding. The safety of this drug in children and adolescents under the age of 18 has not been established, so caution is needed in its use. In cases of overdose, hypotension, dizziness, and tachycardia may occur, and if symptoms are severe, immediate medical treatment should be sought. This medication should be kept out of reach of children, and it is important not to transfer it to another container to maintain quality. Caution should be taken as dizziness may occur when driving or operating machinery.

Side effects

  • Dizziness
  • low back pain
  • respiratory infection
  • upper respiratory tract infection
  • pharyngitis
  • rhinitis
  • weakness
  • fever
  • sensory disturbances
  • dyspepsia
Show 71 more
  • gastroenteritis
  • tachycardia
  • palpitations
  • increased creatine kinase
  • hyperglycemia
  • hypertriglyceridemia
  • hyperuricemia
  • myalgia
  • nasal bleeding
  • anxiety
  • depression
  • somnolence
  • dyspnea
  • rash
  • increased sweating
  • hematuria
  • hypotension
  • hyperkalemia
  • renal function impairment
  • increased creatinine
  • increased urea
  • fatigue
  • peripheral edema
  • chest pain
  • headache
  • bronchitis
  • cough
  • sinusitis
  • nausea
  • abdominal pain
  • diarrhea
  • vomiting
  • arthralgia
  • proteinuria
  • leukopenia
  • neutropenia
  • agranulocytosis
  • hyponatremia
  • hypoglycemia
  • seizures
  • impaired consciousness
  • increased liver enzyme levels
  • hepatitis
  • elevated AST
  • elevated ALT
  • elevated γ-GTP
  • jaundice
  • urticaria
  • pruritus
  • angioedema
  • rhabdomyolysis
  • increased myoglobin
  • acute renal failure
  • interstitial pneumonia
  • shock
  • syncope
  • loss of consciousness
  • paralysis
  • hypertonia
  • facial flushing
  • weight gain
  • facial edema
  • dry mouth
  • sleep disturbances
  • decreased libido
  • amnesia
  • appetite loss
  • increased appetite
  • tinnitus
  • taste disturbance
  • erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

This drug should be stored in a closed container to protect it from air and moisture. It is important to maintain storage temperatures between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Light pink, double convex, round tablet

Package unit

28 tablets (14 tablets/PTP X 2)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.